Unicycive Therapeutics (UNCY) Times Interest Earned (2020 - 2025)
Unicycive Therapeutics posted quarterly Times Interest Earned of -$267.56 for Q4 2025, up 42.22% year-on-year from -$188.13 in Q4 2024, and up 45.34% on a QoQ basis from -$489.47 in Q3 2025.
Unicycive Therapeutics (UNCY) has 6 years of Times Interest Earned data on file, last reported at -$267.56 in Q4 2025.
- For the quarter ending Q4 2025, Times Interest Earned rose 42.22% year-over-year to -$267.56; the trailing twelve-month figure through Mar 2026 stood at -$544.84 (down 16.37% YoY), and the FY2025 full-year result was -$415.73, up 8.1% from the prior year.
- Times Interest Earned for Q4 2025 stood at -$267.56, up from -$489.47 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$2.43 in Q2 2021 and bottomed at -$1851.3 in Q3 2022.
- The 5-year median for Times Interest Earned is -$416.73 (2024), against an average of -$499.56.
- The widest annual swing landed in 2021, when Times Interest Earned soared 98.56%; it then sank 2059.56% in 2022.
- A 5-year view of Times Interest Earned shows it stood at -$85.73 in 2021, then plunged by 1970.52% to -$1775.0 in 2022, then surged by 81.28% to -$332.26 in 2023, then tumbled by 39.36% to -$463.05 in 2024, then jumped by 42.22% to -$267.56 in 2025.
- The last three Times Interest Earned figures came in at -$267.56 (Q4 2025), -$489.47 (Q3 2025), and -$535.62 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -267.56 |
| Sep 30, 2025 | -489.47 |
| Jun 30, 2025 | -535.62 |
| Mar 31, 2025 | -532.60 |
| Dec 31, 2024 | -463.05 |
| Sep 30, 2024 | -416.73 |
| Jun 30, 2024 | -462.56 |
| Mar 31, 2024 | -460.20 |
| Dec 31, 2023 | -332.26 |
| Sep 30, 2023 | -329.89 |
| Jun 30, 2023 | -135.06 |
| Mar 31, 2023 | -350.17 |
| Dec 31, 2022 | -1,775.00 |
| Sep 30, 2022 | -1,851.33 |
| Sep 30, 2021 | -85.73 |
| Jun 30, 2021 | -2.43 |
| Mar 31, 2021 | -2.90 |
| Dec 31, 2020 | -4.40 |
| Sep 30, 2020 | -8.24 |
| Jun 30, 2020 | -168.00 |